371 related articles for article (PubMed ID: 19275964)
1. (3,3-Difluoro-pyrrolidin-1-yl)-[(2S,4S)-(4-(4-pyrimidin-2-yl-piperazin-1-yl)-pyrrolidin-2-yl]-methanone: a potent, selective, orally active dipeptidyl peptidase IV inhibitor.
Ammirati MJ; Andrews KM; Boyer DD; Brodeur AM; Danley DE; Doran SD; Hulin B; Liu S; McPherson RK; Orena SJ; Parker JC; Polivkova J; Qiu X; Soglia CB; Treadway JL; VanVolkenburg MA; Wilder DC; Piotrowski DW
Bioorg Med Chem Lett; 2009 Apr; 19(7):1991-5. PubMed ID: 19275964
[TBL] [Abstract][Full Text] [Related]
2. Metabolism, excretion, and pharmacokinetics of ((3,3-difluoropyrrolidin-1-yl)((2S,4S)-4-(4-(pyrimidin-2-yl)piperazin-1-yl)pyrrolidin-2-yl)methanone, a dipeptidyl peptidase inhibitor, in rat, dog and human.
Sharma R; Sun H; Piotrowski DW; Ryder TF; Doran SD; Dai H; Prakash C
Drug Metab Dispos; 2012 Nov; 40(11):2143-61. PubMed ID: 22896728
[TBL] [Abstract][Full Text] [Related]
3. Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Yoshida T; Akahoshi F; Sakashita H; Kitajima H; Nakamura M; Sonda S; Takeuchi M; Tanaka Y; Ueda N; Sekiguchi S; Ishige T; Shima K; Nabeno M; Abe Y; Anabuki J; Soejima A; Yoshida K; Takashina Y; Ishii S; Kiuchi S; Fukuda S; Tsutsumiuchi R; Kosaka K; Murozono T; Nakamaru Y; Utsumi H; Masutomi N; Kishida H; Miyaguchi I; Hayashi Y
Bioorg Med Chem; 2012 Oct; 20(19):5705-19. PubMed ID: 22959556
[TBL] [Abstract][Full Text] [Related]
4. (2S,4S)-1-[2-(1,1-dimethyl-3-oxo-3-pyrrolidin-1-yl-propylamino)acetyl]-4-fluoro-pyrrolidine-2-carbonitrile: a potent, selective, and orally bioavailable dipeptide-derived inhibitor of dipeptidyl peptidase IV.
Yeh TK; Tsai TY; Hsu T; Cheng JH; Chen X; Song JS; Shy HS; Chiou MC; Chien CH; Tseng YJ; Huang CY; Yeh KC; Huang YL; Huang CH; Huang YW; Wang MH; Tang HK; Chao YS; Chen CT; Jiaang WT
Bioorg Med Chem Lett; 2010 Jun; 20(12):3596-600. PubMed ID: 20483603
[TBL] [Abstract][Full Text] [Related]
5. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Kim D; Wang L; Beconi M; Eiermann GJ; Fisher MH; He H; Hickey GJ; Kowalchick JE; Leiting B; Lyons K; Marsilio F; McCann ME; Patel RA; Petrov A; Scapin G; Patel SB; Roy RS; Wu JK; Wyvratt MJ; Zhang BB; Zhu L; Thornberry NA; Weber AE
J Med Chem; 2005 Jan; 48(1):141-51. PubMed ID: 15634008
[TBL] [Abstract][Full Text] [Related]
6. cis-2,5-dicyanopyrrolidine inhibitors of dipeptidyl peptidase IV: synthesis and in vitro, in vivo, and X-ray crystallographic characterization.
Wright SW; Ammirati MJ; Andrews KM; Brodeur AM; Danley DE; Doran SD; Lillquist JS; McClure LD; McPherson RK; Orena SJ; Parker JC; Polivkova J; Qiu X; Soeller WC; Soglia CB; Treadway JL; VanVolkenburg MA; Wang H; Wilder DC; Olson TV
J Med Chem; 2006 Jun; 49(11):3068-76. PubMed ID: 16722626
[TBL] [Abstract][Full Text] [Related]
7. Discovery of 2-[4-{{2-(2S,5R)-2-cyano-5-ethynyl-1-pyrrolidinyl]-2-oxoethyl]amino]- 4-methyl-1-piperidinyl]-4-pyridinecarboxylic acid (ABT-279): a very potent, selective, effective, and well-tolerated inhibitor of dipeptidyl peptidase-IV, useful for the treatment of diabetes.
Madar DJ; Kopecka H; Pireh D; Yong H; Pei Z; Li X; Wiedeman PE; Djuric SW; Von Geldern TW; Fickes MG; Bhagavatula L; McDermott T; Wittenberger S; Richards SJ; Longenecker KL; Stewart KD; Lubben TH; Ballaron SJ; Stashko MA; Long MA; Wells H; Zinker BA; Mika AK; Beno DW; Kempf-Grote AJ; Polakowski J; Segreti J; Reinhart GA; Fryer RM; Sham HL; Trevillyan JM
J Med Chem; 2006 Oct; 49(21):6416-20. PubMed ID: 17034148
[TBL] [Abstract][Full Text] [Related]
8. (2S,3S)-3-Amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4-[1,2,4]triazolo[1,5-a]-pyridin-6-ylphenyl)butanamide: a selective alpha-amino amide dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Edmondson SD; Mastracchio A; Mathvink RJ; He J; Harper B; Park YJ; Beconi M; Di Salvo J; Eiermann GJ; He H; Leiting B; Leone JF; Levorse DA; Lyons K; Patel RA; Patel SB; Petrov A; Scapin G; Shang J; Roy RS; Smith A; Wu JK; Xu S; Zhu B; Thornberry NA; Weber AE
J Med Chem; 2006 Jun; 49(12):3614-27. PubMed ID: 16759103
[TBL] [Abstract][Full Text] [Related]
9. 1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties.
Villhauer EB; Brinkman JA; Naderi GB; Burkey BF; Dunning BE; Prasad K; Mangold BL; Russell ME; Hughes TE
J Med Chem; 2003 Jun; 46(13):2774-89. PubMed ID: 12801240
[TBL] [Abstract][Full Text] [Related]
10. Novel N-substituted 4-hydrazino piperidine derivative as a dipeptidyl peptidase IV inhibitor.
Gupta RC; Chhipa L; Mandhare AB; Zambad SP; Chauthaiwale V; Nadkarni SS; Dutt C
Bioorg Med Chem Lett; 2009 Sep; 19(17):5021-5. PubMed ID: 19643608
[TBL] [Abstract][Full Text] [Related]
11. (2S,4S)-4-Fluoro-1-{[(2-hydroxy-1,1-dimethylethyl)amino]acetyl}-pyrrolidine-2-carbonitrile monobenzenesulfonate (TS-021) is a selective and reversible dipeptidyl peptidase IV inhibitor.
Tajima A; Yamamoto K; Kozakai A; Okumura-Kitajima L; Mita Y; Kitano K; Jingu S; Nakaike S
Eur J Pharmacol; 2011 Mar; 655(1-3):99-107. PubMed ID: 21262219
[TBL] [Abstract][Full Text] [Related]
12. 7-But-2-ynyl-9-(6-methoxy-pyridin-3-yl)-6-piperazin-1-yl-7,9-dihydro-purin-8-one is a novel competitive and selective inhibitor of dipeptidyl peptidase IV with an antihyperglycemic activity.
Yamazaki K; Yasuda N; Inoue T; Nagakura T; Kira K; Shinoda M; Saeki T; Tanaka I
J Pharmacol Exp Ther; 2006 Dec; 319(3):1253-7. PubMed ID: 16980568
[TBL] [Abstract][Full Text] [Related]
13. ASP4,000, a novel, selective, dipeptidyl peptidase 4 inhibitor with antihyperglycemic activity.
Tanaka-Amino K; Matsumoto K; Hatakeyama Y; Shima I; Takakura S; Muto S
Eur J Pharmacol; 2008 Aug; 590(1-3):444-9. PubMed ID: 18582861
[TBL] [Abstract][Full Text] [Related]
14. Discovery of DA-1229: a potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
Kim HJ; Kwak WY; Min JP; Lee JY; Yoon TH; Kim HD; Shin CY; Kim MK; Choi SH; Kim HS; Yang EK; Cheong YH; Chae YN; Park KJ; Jang JM; Choi SJ; Son MH; Kim SH; Yoo M; Lee BJ
Bioorg Med Chem Lett; 2011 Jun; 21(12):3809-12. PubMed ID: 21570283
[TBL] [Abstract][Full Text] [Related]
15. Discovery of potent, selective, and orally bioavailable quinoline-based dipeptidyl peptidase IV inhibitors targeting Lys554.
Maezaki H; Banno Y; Miyamoto Y; Moritoh Y; Asakawa T; Kataoka O; Takeuchi K; Suzuki N; Ikedo K; Kosaka T; Sasaki M; Tsubotani S; Tani A; Funami M; Yamamoto Y; Tawada M; Aertgeerts K; Yano J; Oi S
Bioorg Med Chem; 2011 Aug; 19(15):4482-98. PubMed ID: 21741847
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor PF-734200 added to metformin in Type 2 diabetes.
Rosenstock J; Lewin AJ; Norwood P; Somayaji V; Nguyen TT; Teeter JG; Johnson SL; Dai H; Terra SG
Diabet Med; 2011 Apr; 28(4):464-9. PubMed ID: 21392067
[TBL] [Abstract][Full Text] [Related]
17. Discovery of ((4R,5S)-5-amino-4-(2,4,5- trifluorophenyl)cyclohex-1-enyl)-(3- (trifluoromethyl)-5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone (ABT-341), a highly potent, selective, orally efficacious, and safe dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Pei Z; Li X; von Geldern TW; Madar DJ; Longenecker K; Yong H; Lubben TH; Stewart KD; Zinker BA; Backes BJ; Judd AS; Mulhern M; Ballaron SJ; Stashko MA; Mika AK; Beno DW; Reinhart GA; Fryer RM; Preusser LC; Kempf-Grote AJ; Sham HL; Trevillyan JM
J Med Chem; 2006 Nov; 49(22):6439-42. PubMed ID: 17064063
[TBL] [Abstract][Full Text] [Related]
18. Identification of 3-aminomethyl-1,2-dihydro-4-phenyl-1-isoquinolones: a new class of potent, selective, and orally active non-peptide dipeptidyl peptidase IV inhibitors that form a unique interaction with Lys554.
Banno Y; Miyamoto Y; Sasaki M; Oi S; Asakawa T; Kataoka O; Takeuchi K; Suzuki N; Ikedo K; Kosaka T; Tsubotani S; Tani A; Funami M; Tawada M; Yamamoto Y; Aertgeerts K; Yano J; Maezaki H
Bioorg Med Chem; 2011 Aug; 19(16):4953-70. PubMed ID: 21764322
[TBL] [Abstract][Full Text] [Related]
19. Discovery of a 3-pyridylacetic acid derivative (TAK-100) as a potent, selective and orally active dipeptidyl peptidase IV (DPP-4) inhibitor.
Miyamoto Y; Banno Y; Yamashita T; Fujimoto T; Oi S; Moritoh Y; Asakawa T; Kataoka O; Yashiro H; Takeuchi K; Suzuki N; Ikedo K; Kosaka T; Tsubotani S; Tani A; Sasaki M; Funami M; Amano M; Yamamoto Y; Aertgeerts K; Yano J; Maezaki H
J Med Chem; 2011 Feb; 54(3):831-50. PubMed ID: 21218817
[TBL] [Abstract][Full Text] [Related]
20. The highly potent and selective dipeptidyl peptidase IV inhibitors bearing a thienopyrimidine scaffold effectively treat type 2 diabetes.
Deng J; Peng L; Zhang G; Lan X; Li C; Chen F; Zhou Y; Lin Z; Chen L; Dai R; Xu H; Yang L; Zhang X; Hu W
Eur J Med Chem; 2011 Jan; 46(1):71-6. PubMed ID: 21106276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
